Evidence map›Paper›PMID 23438961›Full record

ReviewCurrent pharmaceutical design2013

Importance of receptor-targeted systems in the battle against atherosclerosis.

Elisabet Rosas, Igor Sobenin, Alexander Orekhov, Elazer R Edelman, Mercedes Balcells

Abstract readReview
In one paragraph

Review in Current pharmaceutical design, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Elisabet RosasMassachusetts Institute of Technology, Harvard-MIT Biomedical Engineering Center, 77 Massachusetts Avenue, E25-438, Cambridge, MA 02139, US. merche@mit.edu.
Igor Sobenin
Alexander Orekhov
Elazer R Edelman
Mercedes Balcells

Funding

Vascular Drug Delivery - Supplement for EquipmentR01GM049039 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI EDELMAN, ELAZER R · 1994 to 2019
$8.9M
NHLBI NIH HHS R01/HL049039NIGMS NIH HHS R01 GM049039
6 · The paper itself

Abstract

Atherosclerosis is the leading cause of death in the Western World and has been for decades a field of intense research. Yet, while there is a rich and diverse literature describing in detail the players and mechanisms involved in this complex disease in cell and animal models, we remain today with virtually no reliable markers for early diagnosis and targeted treatments options. This review is centered upon the latter. We summarize the latest studies focused on detecting endothelial dysfunction during the early stages of atherosclerosis, when the disease is asymptomatic and describe strategies recently proposed to image and target advanced plaque.

Indexed as

Molecular Targeted TherapyAnimalsAtherosclerosisBiomarkersCell Adhesion MoleculesC-Reactive ProteinCytokinesEarly DiagnosisEndothelium, VascularHumansMatrix MetalloproteinasesNeovascularization, PathologicBiomarkersCell Adhesion MoleculesC-Reactive ProteinCytokinesMatrix Metalloproteinases

Identifiers

PMID23438961
PMCPMC4637971

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.